Autres langues Black Diamond Therapeutics, Inc.

Actions

BDTX

US09203E1055

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 21/08/2026			Varia. 5j.	Varia. 1 janv.
2,210 ^USD	+2,79%		+9,41%	-9,05%

05/08	Black Diamond Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
21/05	Black Diamond Therapeutics annonce des résultats de Phase 2 positifs pour le silevertinib dans le traitement de première ligne du CPNPC présentant des mutations non classiques de l'EGFR	CI

Autres langues

05/08	Black Diamond: Q2 Earnings Snapshot
05/08	Black Diamond Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
05/08	Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
29/06	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Index
29/06	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Value Benchmark
29/06	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 3000E Index
29/06	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 3000E Value Benchmark
29/06	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) dropped from Russell Microcap Growth Benchmark Index
29/06	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 3000 Value Benchmark
29/06	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Dynamic Index
29/06	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell Small Cap Completeness Index
29/06	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell Small Cap Comp Value Benchmark
29/06	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2500 Index
29/06	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2500 Value Benchmark
29/06	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 3000 Index
22/05	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
21/05	Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
21/05	Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients With EGFR Non-Classical Mutations
19/05	Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
19/05	Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
07/05	Black Diamond: Q1 Earnings Snapshot
07/05	Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
07/05	Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
29/04	Olema Pharmaceuticals, Inc. Appoints Prakash Raman, Ph.D., to Board of Directors
21/04	Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting